Full Text View
Tabular View
No Study Results Posted
Related Studies
NAVISTAR® THERMOCOOL® Catheter for the Treatment of Atrial Fibrillation
This study is ongoing, but not recruiting participants.
First Received: June 29, 2005   Last Updated: July 25, 2008   History of Changes
Sponsored by: Biosense Webster, Inc.
Information provided by: Biosense Webster, Inc.
ClinicalTrials.gov Identifier: NCT00116428
  Purpose

This trial compares the safety and effectiveness of catheter ablation for PAF with antiarrhythmic drug therapy. The investigational catheter being studied is the NAVISTAR® THERMOCOOL® irrigated-tip catheter. It is currently FDA-approved for commercial distribution in the U.S. for treating patients with Type I atrial flutter and drug refractory Ventricular Tachycardia for MI patients. The catheter is approved for use in Europe for endocardial ablation for treating cardiac arrhythmias.


Condition Intervention Phase
Heart Diseases
Arrhythmia
Atrial Fibrillation
Device: NAVISTAR® THERMOCOOL® catheter
Phase III

Genetics Home Reference related topics: Brugada syndrome familial atrial fibrillation short QT syndrome
MedlinePlus related topics: Arrhythmia Atrial Fibrillation Heart Diseases
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation

Further study details as provided by Biosense Webster, Inc.:

Estimated Enrollment: 230
Study Start Date: October 2004
Detailed Description:

This is a prospective, randomized, open-label, active-control trial that will enroll up to 230 participants at up to 30 hospitals in the U.S. Patients will be randomized using a 2:1 scheme for the test procedure (ablation)and control (medical therapy) groups, respectively. Patients who fail the trial medication may have an RF ablation procedure according to protocol.

We're trying to improve treatment for atrial fibrillation - you can help!

Do you have episodes of chest pain, palpitations or fainting? This may be due to a condition called "Paroxysmal Atrial Fibrillation". If drug therapy has not been successful to treat this condition or you have intolerable side effects due to medications you are currently taking to treat this condition, you may be eligible for this trial.

What is being studied?

This clinical trial is comparing the safety and effectiveness of a non-drug treatment (medical device) called catheter ablation with the standard drug therapy for AFib. This study is evaluating whether a particular investigational ablation catheter can be used safely and effectively to treat paroxysmal atrial fibrillation.

What does the treatment consist of?

In this procedure, thin flexible tubes (catheters) are inserted into a vein in the groin and threaded into the heart. An attachment at the tip of the catheter delivers electrical energy to the heart tissue. This results in a small, localized burn which modifies the areas of heart muscle essential for starting or maintaining the atrial fibrillation.

Is this treatment dangerous?

All interventional treatments have risks. However, this procedure is widely used for other types of heart rhythm disorders in the U.S. and worldwide with low complication rates. The treatment of paroxysmal atrial fibrillation is a new indication for this particular catheter. Which is why it is the subject of a clinical trial.

I've already failed drug therapy. Can I be in the catheter ablation treatment group?

In order to approve a new treatment, the government requires that "randomized" clinical trials be conducted, comparing the new treatment with the standard of care at the time. In this trial, approximately two-thirds of the patients will receive the ablation treatment, while the remaining patients will be given an antiarrhythmic medication. Those who receive the medication may be eligible to have the ablation treatment at a later date.

Why would I want to take part in this trial?

Currently in the U.S., AFib is primarily treated with drug therapy. But about half of patients treated with antiarrhythmic drugs fail to achieve relief from AFib or find the side effects of the drugs intolerable. The purpose of the study is to demonstrate whether catheter ablation is safe and effective for treating AFib. You would therefore be helping to advance knowledge about the treatment of patients like yourself who have AFib and who are either not getting relief from medications or are unduly bothered by the drug's side effects.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

You may be eligible to participate in this study if you: Have failed to respond to drug treatment for your AFib, or find the side effects of your medication intolerable.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00116428

Locations
United States, Arizona
Arizona Arrhythmia Consultants
Scottsdale, Arizona, United States, 85251
United States, California
Marin General Hospital
Greenbrae, California, United States, 94904
United States, Florida
Florida Hospital
Orlando, Florida, United States, 32803
United States, Illinois
Loyola University Medical Center
Maywood, Illinois, United States, 60153
United States, Kentucky
Central Baptist Hospital
Lexington, Kentucky, United States, 40503
United States, Maryland
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21287
United States, Massachusetts
Brigham and Women's Hospital, Cardiology Division
Boston, Massachusetts, United States, 02115
Lahey Clinic Medical Center
Burlington, Massachusetts, United States, 01805
United States, New York
St. Lukes Roosevelt Hospital
New York, New York, United States, 10025
University of Rochester Medical Center
Rochester, New York, United States, 14642
United States, North Carolina
Wake Forest University School of Medicine
Winston-salem, North Carolina, United States, 27157
United States, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
Ohio State University Medical Center
Columbus, Ohio, United States, 43210
United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States, 17033
United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29425
United States, Texas
Texas Cardiac Arrhythmia Research
Austin, Texas, United States, 78705
United States, Virginia
Inova Fairfax Hospital
Falls Church, Virginia, United States, 22042
Sponsors and Collaborators
Biosense Webster, Inc.
  More Information

No publications provided

Study ID Numbers: BWI03130
Study First Received: June 29, 2005
Last Updated: July 25, 2008
ClinicalTrials.gov Identifier: NCT00116428     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by Biosense Webster, Inc.:
Atrial Fibrillation
Paroxysmal Atrial Fibrillation

Study placed in the following topic categories:
Heart Diseases
Atrial Fibrillation
Arrhythmias, Cardiac

Additional relevant MeSH terms:
Pathologic Processes
Heart Diseases
Cardiovascular Diseases
Atrial Fibrillation
Arrhythmias, Cardiac

ClinicalTrials.gov processed this record on May 07, 2009